Table 2.

Pathological response according to histological and molecular subtype

	No.	pCR breast and axilla	pCR breast
		No. (%)	No. (%)
Histological subtype
Ductal	195	23 (12)	36 (18)
Lobular	42	1 (2)	1 (2)
Adenocarcinoma (NS)	14	5 (36)	8 (57)
Receptor-based subtype
ER-positive (HER2-negative)	138	3 (2)	9 (7)
Triple-negative	57	16 (28)	20 (35)
HER2+	36	3 (8)	5 (14)
HER2+T	20	7 (35)	11 (55)
Total	251	29 (12)	45 (18)

pCR pathological complete remission, ER estrogen receptor, HER2 human epidermal growth factor receptor 2, Triple-negative ER and progesterone receptor (PR) and HER2-negative (triple negative), HER2+T HER2-positive and treated with trastuzumab